FIELD: medicine.
SUBSTANCE: group of inventions relates to medicine, in particular to a drug for the treatment of psoriasis, as well as to a method for its production. The present drug contains from 800 to 1000 g of tallow fat, from 250 to 350 g of larch resin, from 450 to 550 g of beeswax, from 2 to 3 g of gum, from 40 to 50 g of propolis, from 200 to 250 g of Alkanna tinctoria, from 200 to 250 g of alum, from 150 to 200 g of juniper tar.
EFFECT: implementation of the group of inventions allows for expansion of the arsenal of drugs for the treatment of psoriasis, as well as for decrease in a thickness of epidermis, reduction in lymphocyte proliferation, and faster achievement of a positive effect of the treatment.
2 cl, 9 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR FORMING EXPERIMENTAL MODEL OF CHRONIC IMIQUIMOD-INDUCED PSORIASIS-LIKE DERMATITIS IN MICE | 2023 |
|
RU2820279C1 |
| METHOD OF TREATING AUTOIMMUNE DISEASE (VERSIONS) | 2009 |
|
RU2539110C2 |
| AGENT FOR TREATING DISEASE | 2009 |
|
RU2540013C2 |
| THERAPEUTIC AGENT FOR INHIBITION OF PHOSPHODIESTERASE AND ASSOCIATED PATHOLOGICAL DISORDERS | 2018 |
|
RU2815010C2 |
| PHARMACEUTICAL COMPOSITION HAVING THERAPEUTIC EFFECT IN VARIOUS SKIN PATHOLOGIES | 2019 |
|
RU2694059C1 |
| THE METHOD OF PRODUCTION OF INTERLEUKIN-36 RECEPTOR ANTAGONIST WITH CLEAVED N-TERMINAL METHIONINE, ESCHERICHIA COLI BL21[DE3] STRAIN PRODUCING INTERLEUKIN-36 RECEPTOR ANTAGONIST WITH CLEAVED N-TERMINAL METHIONINE (VARIANTS), METHOD OF THEIR CONSTRUCTION, PLASMID VECTORS pBAD15A AND pET15A AND DNA SEQUENCE FOR THEIR CONSTRUCTION | 2017 |
|
RU2672816C9 |
| PSORIASIS THERAPY | 2007 |
|
RU2367429C2 |
| AGENT FOR DISEASE TREATMENT | 2009 |
|
RU2540018C2 |
| METHOD OF TREATING PATIENTS SUFFERING WINTER-TYPE PLAQUE PSORIASIS OF MODERATE AND MILD SEVERITY | 2014 |
|
RU2567725C2 |
| METHOD FOR EVALUATING THE ANTIPSORIATIC EFFECT OF AN EXTERNAL AGENT ON A LABORATORY MODEL OF IMIQUIMOD-INDUCED PSORIASIS | 2021 |
|
RU2764549C1 |
